Predicting the toxicity of a particular compound in a particular individual is an especially complex problem and is subsequently getting a lot of attention these days. Healthcare organizations see the possibility ofreduced costs as patients susceptible to toxic side effects may be screened out before ever receiving a drug. The use of genomics and proteomics information to identify potentially toxic substances and mitigate the risks to patients is called toxico-genomics. As with other genomics fields, toxicogenomics involves the storage, analysis and integration of huge amounts of data.
Toxicogenomics could potentially help reduce the time it takes for drug companies to perform the required safety evaluations on new compounds and perhaps lessen the likelihood of late stage (and expensive) toxicological surprises.
Was this article helpful?